| Literature DB >> 32819400 |
Xu Huang1,2,3,4, Ruoyang Zhang2,5, Guohui Fan2,3,4,6, Dawei Wu7, Haining Lu8, Daoxin Wang9, Wang Deng10, Tongwen Sun11, Lihua Xing12, Shaohua Liu11, Shilei Wang12, Ying Cai2,3,4, Ye Tian2,3,4, Yi Zhang2,3,4, Jingen Xia2,3,4, Qingyuan Zhan13,14,15,16.
Abstract
OBJECTIVES: To evaluate the incidence and mortality of acute respiratory distress syndrome (ARDS) in medical/respiratory intensive care units (MICUs/RICUs) to assess ventilation management and the use of adjunct therapy in routine clinical practice for patients fulfilling the Berlin definition of ARDS in mainland China.Entities:
Keywords: Acute respiratory distress syndrome (ARDS); Diagnosis; Incidence; Lung protective mechanical ventilation
Mesh:
Year: 2020 PMID: 32819400 PMCID: PMC7439799 DOI: 10.1186/s13054-020-03112-0
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 2Incidences of ARDS in different ICUs. The incidences of ARDS varied among different ICUs, with the highest incidence of 16.7% in China-Japan Friendship Hospital and the lowest incidence of 1.0% in the First Affiliated Hospital of Anhui Medical University
Fig. 1Flow of patient screening and enrollment
Characteristics of patients with acute respiratory distress syndrome
| APACHEII | 17.2 ± 7.8 | 15.8 ± 8.6 | 16.1 ± 7.4 | 18.8 ± 7.8 | 0.000 |
| SOFA | 7.4 ± 3.8 | 6.4 ± 3.8 | 6.8 ± 3.7 | 8.2 ± 3.9 | 0.000 |
| Age, mean, years | 55.2 ± 17.4 | 52.7 ± 17.8 | 54.2 ± 17.6 | 57.0 ± 17.0 | 0.065 |
| Men, no. (%) | 369 (70.0) | 26 (51.0) | 185 (74.0) | 158 (69.9) | 0.005 |
| BMI | 24.2 ± 4.6 | 23.6 ± 5.1 | 24.3 ± 4.6 | 24.2 ± 4.4 | 0.282 |
| Obesity, no. (%) | 65 (12.4) | 4 (8.0) | 29 (11.7) | 32 (14.2) | 0.4297 |
| Chronic lung diseases | 30 (5.7) | 0 (0.0) | 15 (6.0) | 15 (6.7) | 0.151 |
| Hypertension | 176 (33.6) | 12 (23.5) | 79 (31.6) | 85 (38.1) | 0.090 |
| Diabetes | 101 (19.3) | 8 (15.7) | 56 (22.4) | 37 (16.7) | 0.228 |
| Coronary diseases | 57 (10.9) | 0 (0.0) | 25 (10.0) | 32 (14.3) | 0.010 |
| Chronic cardiac failure | 26 (5.0) | 2 (3.9) | 14 (5.6) | 10 (4.5) | 0.806 |
| Cerebral vascular diseases | 52 (9.9) | 1 (2.0) | 32 (12.8) | 19 (8.5) | 0.040 |
| Chronic renal failure | 56 (10.7) | 5 (9.8) | 22 (8.8) | 29 (13.1) | 0.315 |
| Liver cirrhosis | 21 (4.0) | 1 (2.0) | 14 (5.6) | 6 (2.7) | 0204 |
| Connective tissue diseases | 35 (6.7) | 1 (2.0) | 20 (8.0) | 14 (6.3) | 0.275 |
| Active neoplasm | 41 (7.8) | 5 (9.8) | 16 (6.4) | 20 (9.0) | 0.500 |
| Alcohol use disorder | 21 (4.0) | 2 (3.9) | 15 (6.0) | 4 (1.8) | 0.051 |
| Smoking | 180 (34.4) | 15 (29.4) | 90 (36.0) | 75 (33.6) | 0.636 |
APACHE acute physiology and chronic health evaluation, SOFA sequential organ failure assessment, BMI body weight index
aP value represents comparisons across the ARDS severity categories for each variable
Risk factors for acute respiratory distress syndrome
| Risk factors for ARDS | ||||
| Intrapulmonary | 441 (83.7) | 37 (72.5) | 207 (82.8) | 197 (87.2) |
| Pneumonia | 402 (77.0) | 32 (64.0) | 183 (73.5) | 187 (83.9) |
| Aspiration | 17 (3.3) | 1 (2.0) | 11 (4.4) | 5 (2.2) |
| Drowning | 3 (0.6) | 0 (0.0) | 3 (1.2) | 0 (0.0) |
| Pulmonary contusion | 10 (1.9) | 3 (6.0) | 6 (2.4) | 1 (0.4) |
| Others | 9 (1.7) | 1 (2.0) | 4 (1.6) | 4 (1.8) |
| Extrapulmonary | 86 (16.3) | 14 (27.5) | 43 (17.2) | 29 (12.8) |
| Trauma | 8 (1.5) | 0 (0.0) | 7 (2.8) | 1 (0.4) |
| Extra pulmonary sepsis | 38 (7.3) | 7 (14.0) | 18 (7.2) | 13 (5.8) |
| Pancreatitis | 18 (3.4) | 5 (10.0) | 9 (3.6) | 4 (1.8) |
| Non-cardiogenic shock | 1 (0.2) | 0 (0.0) | 1 (0.4) | 0 (0.0) |
| Blood transfusion | 2 (0.4) | 1 (2.0) | 1 (0.4) | 0 (0.0) |
| Others | 23 (4.4) | 1 (2.0) | 10 (4.0) | 12 (5.4) |
ARDS acute respiratory distress syndrome
Characteristics of ARDS patients treated with invasive ventilation and use of adjunctive by severity category
| D1 IPPV | 299 (56.7) | 25 (49.0) | 125 (50.0) | 149 (65.9) | 0.001 |
| IPPV during ICU | 400 (75.9) | 30 (58.8) | 177 (70.8) | 193 (85.4) | 0.000 |
| Mode on 1st day of IPPV | |||||
| Volume control ventilation | 55 (13.8) | 3 (10.0) | 22 (12.4) | 30 (13.8) | |
| Pressure control ventilation | 192 (48.0) | 11 (36.7) | 81 (45.8) | 100 (51.8) | |
| SIMV+PS | 47 (11.8) | 4 (13.3) | 18 (10.2) | 25 (13.0) | |
| Pressure support ventilation | 70 (17.5) | 7 (23.3) | 36 (20.3) | 27 (14.0) | |
| Bilevel | 32 (8.0) | 5 (16.7) | 18 (10.2) | 9 (4.7) | |
| Other modes | 4 (1.0) | 0 (0.0) | 2 (1.1) | 2 (1.0) | |
| PEEP median (IQR), cmH2O | 8 (6–12) | 7 (5–8) | 8 (6–10) | 10 (6–12) | 0.000 |
| 6.8 (5.8–7.9) | 7.0 (6.6–7.7) | 6.8 (5.9–8.0) | 6.8 (5.8–7.9) | 0.538 | |
| Plateau pressure, median (IQR), cmH2O | 20 (16–26) | 20 (15–23) | 20 (15–25) | 22 (18–27) | 0.220 |
| Driving pressurea, median (IQR), cmH2O | 12 (8–16) | 14 (10–15) | 13 (8–16) | 12 (8–17) | 0.779 |
| Airway resistancea, median (IQR) cmH2O/L/S | 12.0 (8.0–18.2) | 12.0 (9.7–17.0) | 11.0 (7.8–19.0) | 12.0 (8.0–18.0) | 0.571 |
| Compliancea, median (IQR) ml/cmH2O | 35.0 (25.0–43.7) | 36.4 (30.7–43.0) | 36.4 (24.0–52.0) | 32.0 (25.0–42.0) | 0.191 |
| ABG, D1 ARDS | |||||
| PaO2/FIO2, median (IQR), mmHg | 113 (80–161) | 227 (206–270) | 142 (115–166) | 78 (59–96) | 0.000 |
| PaCO2, median (IQR), mmHg | 36.3 (31.2–42.7) | 36.2 (29.6–39.0) | 35.9 (31.0–41.5) | 37.2 (31.8–45.2) | 0.044 |
| pH, median (IQR) | 7.42 (7.36–7.46) | 7.43 (7.36–7.48) | 7.2 (7.36–7.46) | 7.41 (7.40–7.46) | 0.651 |
| NMBAs | 107 (26.8) | 5 (16.7) | 43 (24.3) | 59 (30.6) | 0.177 |
| RM | 61 (15.3) | 2 (6.7) | 26 (14.7) | 33 (17.1) | 0.322 |
| PPV | 85 (21.3) | 3 (10.0) | 29 (16.4) | 53 (27.5) | 0.011 |
| ECMO | 61 (15.3) | 2 (6.7) | 23 (13.0) | 36 (18.7) | 0.142 |
| HFOV | 3 (0.8) | 0 (0.0) | 1 (0.6) | 2 (1.0) | 1.000 |
| High-dose corticosteroidc | 157 (29.8) | 13 (25.5) | 59 (23.6) | 85 (37.6) | 0.003 |
IPPV invasive positive pressure ventilation, ICU intensive care unit, SIMV synchronized intermittent mandatory ventilation, PS pressure support, PEEP positive end-expiratory pressure, VT tidal volume, PBW predicted body weight, ABG arterial blood gas, NMBAs neuromuscular blockade, RM lung recruitment manoeuvre, PPV prone position ventilation, EMCO extracorporeal membrane oxygenation, HFOV high-frequency oscillatory ventilation
aPlateau pressure values, driving pressure values, airway resistance values, and respiratory compliance values are limited to patients in whom this value was reported. The number of measured patients is 211 cases. Patients receiving HFOV or ECMO were also excluded
bP value represents comparisons across the ARDS severity categories for each variable
cHigh-dose corticosteroids was defined as doses that were equal to or greater than the equivalent of 1 mg/kg of prednisolone
Outcomes of invasively ventilated patients by acute respiratory distress syndrome severity at diagnosis
| Progression of ARDS severity | |||||
| Progression to moderate | 26/51 (51.0) | 26/51 (51.0) | – | – | |
| Progression to severe | 128/301 (42.5) | 16/51 (31.4) | 112/250 (44.8) | – | |
| Invasive ventilation-free days to day 28, median (IQR), days | 6 (0–22) | 21 (0–28) | 12 (0–23) | 0 (0–18) | 0.000 |
| IPPV barotrauma | 31 (7.8) | 1 (3.3) | 15 (8.5) | 15 (7.7) | 0.5621 |
| Subcutaneous emphysema | 14 (2.6) | 0 (0.0) | 7 (2.8) | 7 (3.0) | 0.2362 |
| Mediastinal emphysema | 19 (3.6) | 0 (0.0) | 8 (3.2) | 11 (4.8) | 0.0946 |
| Pneumothorax | 23 (4.3) | 1 (2.0) | 11 (4.4) | 11 (4.8) | 0.6149 |
| HAI | 135 (25.6) | 9 (17.6) | 58 (23.2) | 68 (30.1) | 0.089 |
| HAP | 117 (22.3) | 6 (12.0) | 50 (20.0) | 61 (27.2) | 0.031 |
| CRBSI | 23 (4.4) | 2 (4.0) | 9 (3.6) | 12 (5.4) | 0.640 |
| BSI | 31 (5.9) | 3 (5.9) | 12 (4.8) | 16 (7.1) | 0.5889 |
| Intra-abdominal infection | 10 (1.9) | 1 (2.0) | 5 (2.0) | 4 (1.8) | 0.983 |
| Other HAI | 15 (3.0) | 1 (2.0) | 8 (3.3) | 6 (2.8) | 0.879 |
| Organ failure | |||||
| At least one extrapulmonary organ failure | 241 (45.7) | 15 (29.4) | 104 (41.6) | 122 (54.0) | 0.001 |
| Shock | 191 (36.3) | 14 (27.5) | 84 (33.2) | 94 (41.8) | 0.058 |
| Kidney | 130 (24.7) | 5 (9.8) | 61 (24.4) | 64 (28.4) | 0.020 |
| CRRT | 119 (22.6) | 10 (19.6) | 54 (21.6) | 55 (24.3) | 0.568 |
| Liver | 57 (10.8) | 5 (9.8) | 22 (8.8) | 30 (13.3) | 0.275 |
| Coagulation | 64 (12.2) | 5 (9.8) | 31 (12.4) | 28 (12.4) | 0.863 |
| GCS | 38 (7.3) | 4 (7.8) | 14 (5.6) | 20 (9.0) | 0.378 |
| ICU length of stay, median (IQR), days | 11 (7, 21) | 7 (5, 17) | 12 (7, 20) | 12 (6, 21) | 0.080 |
| ICU mortalityc | 232 (44.0) | 15 (29.4) | 96 (38.4) | 121 (53.5) | 0.000 |
| Hospital length of stay, median (IQR), days | 19 (10, 29) | 15 (9, 23) | 20 (12, 30) | 17 (9, 29) | 0.049 |
| Hospital mortalityc | 244 (46.3) | 16 (31.4) | 101 (40.4) | 127 (56.2) | 0.000 |
| Withdrawal of life sustaining careb | 92 (17.5) | 5 (9.8) | 38 (15.2) | 49 (21.7) | 0.021 |
| Patients except withdrawal | |||||
| ICU mortality | 140 (32.2) | 10 (21.7) | 58 (27.4) | 72 (40.7) | 0.005 |
| Hospital mortality | 152 (34.9) | 11 (23.9) | 63 (29.7) | 78 (44.1) | 0.003 |
ARDS acute respiratory distress syndrome, IPPV invasive positive pressure ventilation, HAI hospital-acquired infection, HAP hospital-acquired pneumonia, CRBSI catheter-related blood stream infection, BSI blood stream infection, CRRT continuous renal replacement therapy, GCS Glasgow coma scale, ICU intensive care unit; organ failure: SOFA scores ≥ 3 referring to one organ were defined as failure of that organ
aP value represents comparisons across the ARDS severity categories for each variable
bAll the withdrawal of life sustaining care patients discharged from the hospital were confirmed dead on the day of withdrawal
cWhen ICU and hospital mortality were calculated, the withdrawal patients were included
Fig. 3Probability of hospital survival by ARDS severity. Survival curve showed a lower likelihood of survival in severe group compared with mild and moderate groups on day 1